Sugi Predict

Sugi Predict / Compounds / SCHEMBL4520980

SCHEMBL4520980

SCHEMBL4520980

CC(=O)Oc1ccc(N)cc1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 1/20 0.46
▸ ALDH1A1 P00352 4/20 0.46
▸ TSHR P16473 3/20 0.46
▸ KDM4E B2RXH2 3/20 0.46
▸ GAA P10253 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ PDE10A Q9Y233 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ CFD P00746 2/20 0.44
▸ CYP19A1 P11511 1/20 0.44
▸ NR3C1 P04150 1/20 0.42
▸ CASP1 P29466 1/20 0.41
▸ KMT2A Q03164 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1469593 0.85 ACHE (0.59) ACHEALDH1A1TSHRKDM4EGAA
SCHEMBL2191597 0.85 PDE10A (0.45) ALDH1A1TSHRKDM4EGAAPDE10A
SCHEMBL10917992 0.85 PDE10A (0.45) ALDH1A1TSHRKDM4EGAAPDE10A
SCHEMBL6247630 0.84 TSHR (0.58) ALDH1A1TSHRKDM4EGAARAB9A
SCHEMBL19903990 0.84 PDE10A (0.41) ALDH1A1TSHRKDM4EGAAPDE10A
SCHEMBL987450 0.82 ALDH1A1 (0.47) ACHEALDH1A1TSHRKDM4EGAA
SCHEMBL28960611 0.81 CYP1A2 (0.49) ALDH1A1GAARAB9APDE10AKMT2A
SCHEMBL17072170 0.81 GAA (0.49) ALDH1A1TSHRKDM4EGAARAB9A
SCHEMBL20695472 0.80 LMNA (0.51) TSHRPDE10AKMT2ALMNAMAPT
SCHEMBL28756384 0.80 ACHE (0.50) ACHEALDH1A1KDM4EGAAPDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117164745-A Composite material for microporous membrane, composite ion exchange membrane and application of composite material 国家电投集团氢能科技发展有限公司 2023-12-05 — — CN claimed
CN-117126311-A Polymer, composite, ion exchange membrane and preparation method and application thereof 国家电投集团氢能科技发展有限公司 2023-11-28 — — CN claimed
CN-116808842-B Modified microporous membrane, composite ion exchange membrane, and preparation methods and applications thereof 国家电投集团氢能科技发展有限公司 2023-10-27 — — CN claimed
CN-116808842-A Modified microporous membrane, composite ion exchange membrane, and preparation methods and applications thereof 国家电投集团氢能科技发展有限公司 2023-09-29 — — CN claimed
CN-117164745-A Composite material for microporous membrane, composite ion exchange membrane and application of composite material 国家电投集团氢能科技发展有限公司 2023-12-05 — — CN disclosed
CN-117126311-A Polymer, composite, ion exchange membrane and preparation method and application thereof 国家电投集团氢能科技发展有限公司 2023-11-28 — — CN disclosed
CN-116808842-B Modified microporous membrane, composite ion exchange membrane, and preparation methods and applications thereof 国家电投集团氢能科技发展有限公司 2023-10-27 — — CN disclosed
CN-116808842-A Modified microporous membrane, composite ion exchange membrane, and preparation methods and applications thereof 国家电投集团氢能科技发展有限公司 2023-09-29 — — CN disclosed
EP-2636675-B1 DIPHOSPHONATE COMPOUNDS AND PREPARATION METHOD AND USE THEREOF CHENGDU YUNKE PHARMACEUTICAL CO LTD (CN) 2016-05-18 — — EP disclosed
US-20150148377-A1 Quinoline Derivatives NOVARTIS AG (CH) 2015-05-28 — — US disclosed
US-20150148377-A1 Quinoline Derivatives NOVARTIS AG (CH) 2015-05-28 — — US disclosed
US-20150148377-A1 Quinoline Derivatives NOVARTIS AG (CH) 2015-05-28 — — US disclosed
EP-2794594-A1 QUINOLINE DERIVATIVES Novartis AG (CH) 2014-10-29 — — EP disclosed
EP-2636675-A1 DIPHOSPHONATE COMPOUNDS AND PREPARATION METHOD AND USE THEREOF Chengdu Yunke Pharmaceutical Co., Ltd (CN) 2013-09-11 — — EP disclosed
WO-2013093850-A1 QUINOLINE DERIVATIVES NOVARTIS AG (CH) 2013-06-27 — — WO disclosed
WO-2013093850-A1 QUINOLINE DERIVATIVES NOVARTIS AG (CH) 2013-06-27 — — WO disclosed
US-7576175-B2 Amino acid terminated diphenylurea derivatives; display high binding affinity, specificity, and stability; use in treating cancer, inflammatory diseases, and autoimmune diseases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-08-18 — — US disclosed
WO-2005122379-A9 ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY UNIV CALIFORNIA (US) 2006-03-09 — — WO disclosed
US-20060019900-A1 Alpha-4 beta-1 integrin ligands for imaging and therapy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-01-26 — — US disclosed
WO-2005122379-A2 ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-12-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019900-A1 Alpha-4 beta-1 integrin ligands for imaging and therapy ITGA4, ITGB4, ITGA1 ACHE 4118/4885ALDH1A1 1238/4885TSHR 1254/4885
US-20150148377-A1 Quinoline Derivatives RECQL, NQO2, PIK3R3 ACHE 483/4885ALDH1A1 2856/4885TSHR 2027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.